Literature DB >> 2186179

Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats.

G A Prince1, V G Hemming, R L Horswood, P A Baron, B R Murphy, R M Chanock.   

Abstract

Antibody-mediated clearance of respiratory syncytial virus from cotton rat pulmonary tissues occurs in the absence of complement and in the absence of the Fc portion of the immunoglobulin G molecule, suggesting that complement-independent, cell-independent neutralization is the major mechanism of clearance.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2186179      PMCID： PMC249499     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  7 in total

1.  Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model.

Authors:  V G Hemming; G A Prince; R L Horswood; W J London; B R Murphy; E E Walsh; G W Fischer; L E Weisman; P A Baron; R M Chanock
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

2.  Passive transfer of antiviral antibodies restricts replication of Aleutian mink disease parvovirus in vivo.

Authors:  S Alexandersen; S Larsen; A Cohn; A Uttenthal; R E Race; B Aasted; M Hansen; M E Bloom
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; V G Hemming; R L Horswood; P A Baron; R M Chanock
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

4.  Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

Authors:  G A Prince; V G Hemming; R L Horswood; R M Chanock
Journal:  Virus Res       Date:  1985-10       Impact factor: 3.303

5.  The pathogenesis of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; A B Jenson; R L Horswood; E Camargo; R M Chanock
Journal:  Am J Pathol       Date:  1978-12       Impact factor: 4.307

6.  Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children.

Authors:  V G Hemming; W Rodriguez; H W Kim; C D Brandt; R H Parrott; B Burch; G A Prince; P A Baron; R J Fink; G Reaman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 7.  Neutralization of animal viruses.

Authors:  B Mandel
Journal:  Adv Virus Res       Date:  1978       Impact factor: 9.937
  7 in total
  10 in total

1.  Immunologic correlates of protection against rotavirus challenge after intramuscular immunization of mice.

Authors:  S E Coffin; C A Moser; S Cohen; H F Clark; P A Offit
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

3.  Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice.

Authors:  K Sudo; W Watanabe; K Konno; R Sato; T Kajiyashiki; S Shigeta; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Induction of mucosal B-cell memory by intramuscular inoculation of mice with rotavirus.

Authors:  S E Coffin; P A Offit
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Diane E Griffin
Journal:  J Gen Virol       Date:  2016-09-22       Impact factor: 3.891

Review 6.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.

Authors:  J E Crowe; B R Murphy; R M Chanock; R A Williamson; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

8.  Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2.

Authors:  S Corbeil; C Seguin; M Trudel
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

Review 10.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.